The case for low-level BACE1 inhibition for the prevention of Alzheimer disease | Nature Reviews Neurology
Frontiers | Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment | Chemistry
IJMS | Free Full-Text | Natural Products Targeting Amyloid Beta in Alzheimer's Disease | HTML
Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease* - Journal of Biological Chemistry
Current status of anti-Alzheimer's disease drugs in trials | Download Scientific Diagram
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. - Abstract - Europe PMC
A Perspective on Multi-target Drugs for Alzheimer's Disease: Trends in Pharmacological Sciences
A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease | EMBO Molecular Medicine
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease - Moussa‐Pacha - 2020 - Medicinal Research Reviews - Wiley Online Library
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease - Chemical Society Reviews (RSC Publishing)
The β-Secretase BACE1 in Alzheimer's Disease - Biological Psychiatry
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease | Semantic Scholar
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease | Alzheimer's Research & Therapy | Full Text
Alzheimer's Disease Insight Report: Current Therapies, Drug Pipeline and Outlook
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease | Alzheimer's Research & Therapy | Full Text
Alzheimer's disease: clinical trials and drug development - The Lancet Neurology
Critical analysis of the use of β-site amyloid precursor protein- | DNND
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease | Semantic Scholar
Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein - ScienceDirect
Expert Insights: Another Failure for BACE1 Drugs Raises Questions about Alzheimer's Disease Treatments - Clinical Trials Arena
Frontiers | Targeting Amyloidogenic Processing of APP in Alzheimer's Disease | Molecular Neuroscience
Why are BACE1 inhibitors failing clinical trials?
BACE1 Inhibitors in Phase 3 Trials for Alzheimer's are Safe in Moderate Doses, According to Study - Alzheimer's News Today
